Showing results (571-580 of 1,188) with videos related to

Sort By:
Pageof 119
Pharmaceutical Statistics|September 29, 2026
BEACON: An Adaptive Bayesian Early-Phase Oncology Trial Design Integrating Dose Optimization and Proof-of-Concept Across Survival and Binary EndpointsYike Tang, Feng Tian, Xiaochen Zhu, et al.
Pharmaceutical Statistics|September 14, 2026
The Impact of Enrollment Strategies on the Performance of Time-To-Event Dose-Escalation Designs for Phase I Drug Combination Oncology TrialsXiaowen Tian, Michael Sweeting, Kristine Broglio
Pharmaceutical Statistics|September 17, 2026
Sensitivity of Responder Effects to Different Thresholds and Control Group Means on Patient-Reported Outcomes: Varying Group Standard DeviationsJoseph C Cappelleri, Jia Ma, Manuela Di Fusco, et al.
Pharmaceutical Statistics|September 20, 2026
A Seamless Phase I/II Design With Randomization for Biomarker-Guided Oncology TrialsEmily C Zabor, Sneha Govande, Wen Wee Ma, et al.
Pharmaceutical Statistics|November 24, 2021
Bivariate Bayesian hypothesis testing with missing data in componentsZhixing Xu, Hui Quan
Pharmaceutical Statistics|November 10, 2021
A note on point estimation and interval estimation of the relative treatment effect under a simple crossover designChii-Dean Lin, Kung-Jong Lui
Pharmaceutical Statistics|March 19, 2021
Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agentsThomas A Murray
Pharmaceutical Statistics|December 3, 2021
Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequenceJoanne C Rothwell, Steven A Julious, Cindy L Cooper
Pharmaceutical Statistics|December 4, 2021
TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity gradesKentaro Takeda, Qing Xia, Shufang Liu, et al.
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.
Pageof 119